Table 1

Treatment Effect by Troponin T (TnT) Status in Various Studies (32)

NStudy DesignPopulationDeath or MI, TnT (+)Relative Reduction
TreatmentControl
PRISM (30)2222RetrospectiveACS3.5%13.7%74%
CAPTURE (26,33)1265RetrospectiveACS + PCI5.8%19.6%70%
PARAGON-B (32)1160ProspectiveACS11.0%19.0%42%
PRISM-PLUS*110RetrospectiveACS3.6%20.6%71%
GUSTO IV ACS7707ProspectiveACS10.5%10.7%

ACS = acute coronary syndromes; CAPTURE = Chimeric c7E3 AntiPlatelet Therapy in Unstable REfractory angina; GUSTO = Global Utilization of Strategies To open Occluded arteries; MI = myocardial infarction; PARAGON = Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network; PCI = percutaneous coronary intervention; PRISM-PLUS = Platelet Receptor inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms.

  • * Januzzi JL, personal communication. February 21, 2001.

  • The GUSTO IV ACS Investigators; Presented at the XXII Congress of the European Society of Cardiology, August 2000. Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B Troponin T Substudy. Circulation 2001;103:2891–96.